Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Safety and efficacy of idasanutlin in PV

Abdulraheem Yacoub • 9 Dec 2020
ASH 2020
Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Idasanutlin

Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, reports the results of the Phase II study (NCT03287245) of idasanutlin, an inhibitor of MDM2 which causes P53 activation in patients with hypoxyurea resistant/intolerant polycythemia vera. Although the inhibitor has demonstrated profound efficiency and therapeutic effect, low-grade gastrointestinal toxicity was observed which could not be managed effectively. Dr Yacoub goes on to discuss future directions for utilizing the novel therapy to serve patients experiencing this toxicity. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

More from Abdulraheem Yacoub

2:06
Parsaclisib plus ruxolitinib in myelofibrosis: a promising strategy for treatment-naive patients
Abdulraheem Yacoub • 26 Aug 2022
2:42
The management of advanced phase MPNs
Abdulraheem Yacoub • 26 Aug 2022
4:15
The latest data on momelotinib for MPNs
Abdulraheem Yacoub • 10 Aug 2021
4:11
Novel therapies and combinations for myelofibrosis patients
Abdulraheem Yacoub • 10 Aug 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals